(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 September 2025 (04.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/184419 A1

(51) International Patent Classification:
A61K 38/17 (2006.01) *C07K 14/47* (2006.01)
A61P 27/02 (2006.01)

(21) International Application Number:
PCT/US2025/017711

(22) International Filing Date:
27 February 2025 (27.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/559,733 29 February 2024 (29.02.2024) US

(71) Applicant: **KODIAK SCIENCES INC.** [US/US]; 1250 Page Mill Road, Palo Alto, California 94304 (US).


(72) Inventors: **CHO, Catherine, M.**; c/o Kodiak Sciences Inc., 1250 Page Mill Road, Palo Alto, California 94304 (US). **DEVAY JACOBSON, Rachel Marie**; c/o Kodiak Sciences Inc., 1250 Page Mill Road, Palo Alto, California 94304 (US). **LIANG, Hong**; c/o Kodiak Sciences Inc., 1250 Page Mill Road, Palo Alto, California 94304 (US). **PERL-ROTH, Daniel Victor**; c/o Kodiak Sciences Inc., 1250 Page Mill Road, Palo Alto, California 94304 (US). **CORRÊA, Fernando**; c/o Kodiak Sciences Inc., 1250 Page Mill Road, Palo Alto, California 94304 (US). **CHANG, Dolly Shuo-Teh**; c/o Kodiak Sciences Inc., 1250 Page Mill Road, Palo Alto, CA 94304 (US).

(74) Agent: **LOZAN, Vladimir, S.**; Knobbe, Martens, Olson & Bear, LLP , 2040 Main Street, 14th Floor, Irvine, California 92614 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) **Title:** ENGINEERED COMPLEMENT INHIBITOR PROTEINS

Figure 19



(57) **Abstract:** Provided herein are protein inhibitors of the complement system and methods of use thereof. In some embodiments, the protein inhibitors can reduce inflammation and tissue damage in conditions including macular degeneration. In some embodiments, the protein inhibitors comprise oligomerization domains or complement receptor domains covalently linked to CCP domains from CR1, FH, CFHR1, CFHR3 and/or CFHR5.

[Continued on next page]

WO 2025/184419 A1

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*